Erythropoietin (EPO) is a glycoprotein hormone that regulates hematopoiesis in the human
body. The presence of EPO and its receptors in different tissues indicates that this hormone …

Purpose To summarize the existing treatment options regarding central retinal artery
occlusion (CRAO), branch retinal artery occlusion (BRAO), arteritic anterior ischemic optic …

Background Nonarteritic anterior ischemic optic neuropathy (NAAION) is a major cause of
blindness in individuals over 50 years of age, with no available effective treatment. The oral …

Objective To review treatment modalities that have been studied in acute non arteritic
anterior ischemic optic neuropathy (NAION). Methods We performed a comprehensive …

Erythropoietin (EPO) is known as a hormone for erythropoiesis in response to anemia and
hypoxia. However, the effect of EPO is not only limited to hematopoietic tissue. Several …

Purpose Despite various therapeutic attempts, an approved treatment for Methanol-induced
optic neuropathy (MION), a sight-threatening disorder, is still lacking. Erythropoietin known …

The treatment of arteritic anterior ischemic optic neuropathy (AAION), non-arteritic ischemic
optic neuropathy (NAAION), and posterior ischemic optic neuropathy (PION) is a topic of …

Purpose Nonarteritic anterior ischemic optic neuropathy (NAION) is the second most
common form of optic neuropathy. Most patients show no improvement over time. Until now …

Background and purpose The objective of this investigation was to assess the therapeutic
efficacy of distinct glucocorticoid therapy dosages in the management of acute nonarteritic …

Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common acute
unilateral optic nerve (ON)-related cause of vision loss in people over age 50 (1, 2) …